Tag: Human Papilloma Virus (HPV)

1. In this national survey, both pediatricians and family physicians (FPs) were more likely to make a strong recommendation for the human papilloma virus (HPV) vaccine in older adolescents as compared to younger adolescents (ages 11 to 12 years). Pediatricians were more likely than FPs to use a presumptive...
Genetically engineered T-cell therapies, such as chimeric antigen receptor T-cells (CAR T-cells), have been approved for the treatment of hematologic malignancies, however, there are limited data to support this approach in the management of epithelial cancers. Human papillomavirus (HPV)-associated epithelial cancers express viral E6 and E7 oncoproteins, which are...
1. A 3-dose regimen of 4-valent human papillomavirus (4vHPV) vaccine administered between the ages of 9-15 years of age was shown to be immunogenic, clinically effective, and without significant adverse effects throughout a 10-year follow-up period.  2. Immunogenic response was most robust when the vaccine was administered during the preadolescent period when...
1. Physicians who used an announcement technique when introducing human papillomavirus (HPV) vaccination had a higher rate of vaccination coverage compared to other techniques. 2. The announcement technique involves stating that vaccinations will be given without inviting questions from patients. Evidence Rating Level: 1 (Excellent)             Study Rundown: Vaccine uptake for the...
1. A greater proportion of teenage girls initiated the human papillomavirus (HPV) vaccine series in states where the tetanus, diphtheria, and pertussis (Tdap) booster and/or the meningococcal vaccine were required for school entry. 2. State laws requiring HPV vaccination but allowing for exemptions for any reason have not been effective...
1. There was a significant decline noted in the prevalence of the human papillomavirus (HPV) types 6, 11, 16, and 18 (those found in the quadrivalent HPV vaccine) among women ages 14 to 24 years between the pre- and post-vaccine time periods. 2. The prevalence of these quadrivalent HPV types (4vHPV)...
1. In U.S. adolescent males, human papillomavirus (HPV) vaccination uptake of ≥1 dose and series completion of ≥3 doses were 34.6% and 13.9%, respectively, with significantly higher rates of completion among non-Hispanic blacks and Hispanics, compared with non-Hispanic whites. 2. The most common reason reported by parents for not vaccinating...
1. Simultaneous administration of the 9-valent human papillomavirus (HPV) vaccine with Tdap (tetanus/diphtheria/acellular pertussis) and Menactra (Neisseria meningitidis) resulted in a noninferior antibody response compared to non-simultaneous injections. 2. There was no statistical difference in vaccine-related serious adverse events between the two groups, although concomitant injection did result in more...
1. Radiographic evidence of matted nodes was a significant independent predictor for distant failure and case-specific mortality in patients who were treated for oropharyngeal cancer with definitive chemotherapy. 2. Lack of matted nodes was associated with minimal distant failure risk. Evidence Rating Level:  2 (Good) Study Rundown: The incidence of human papillomavirus...
1. Oral oncogenic HPV prevalence was more than 4 times higher among men than women. 2.The gender difference was due primarily to a higher number of lifetime sexual partners and a stronger association between sexual behavior and infection among men. Evidence Rating Level: 3 (Average) Study Rundown: It is widely known that the...